|
1
|
Tryfonidis K, Basaran G, Bogaerts J,
Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D,
Cufer T, Piccart M, et al: A European organisation for research and
treatment of cancer randomized, double-blind, placebo-controlled,
multicentre phase II trial of anastrozole in combination with
gefitinib or placebo in hormone receptor-positive advanced breast
cancer (NCT00066378). Eur J Cancer. 53:144–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dieras V, Wildiers H, Jassem J, Dirix LY,
Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani
SA, et al: Trebananib (AMG 386) plus weekly paclitaxel with or
without bevacizumab as first-line therapy for HER2-negative locally
recurrent or metastatic breast cancer: A phase 2 randomized study.
Breast. 24:182–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu J, Wang JG, Zhang L, Yang HP, Wang L,
Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al: MicroRNA-320a
inhibits breast cancer metastasis by targeting metadherin.
Oncotarget. 7:38612–38625. 2016.PubMed/NCBI
|
|
4
|
Mathe A, Scott RJ and Avery-Kiejda KA:
MiRNAs and other epigenetic changes as biomarkers in triple
negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He BS, Pan YQ, Lin K, Ying HQ, Wang F,
Deng QW, Sun HL, Gao TY and Wang SK: Evaluation the susceptibility
of five polymorphisms in microRNA-binding sites to female breast
cancer risk in Chinese population. Gene. 573:160–165. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams BD, Parsons C and Slack FJ: The
tumor-suppressive and potential therapeutic functions of miR-34a in
epithelial carcinomas. Expert Opin Ther Targets. 20:737–753. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Javeri A, Ghaffarpour M, Taha MF and
Houshmand M: Downregulation of miR-34a in breast tumors is not
associated with either p53 mutations or promoter hypermethylation
while it correlates with metastasis. Med Oncol. 30:4132013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kato M, Paranjape T, Muller RU, Nallur S,
Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB and Slack FJ:
The mir-34 microRNA is required for the DNA damage response in vivo
in C. Elegans and in vitro in human breast cancer cells. Oncogene.
28:2419–2424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vogt M, Munding J, Gruner M, Liffers ST,
Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A and Hermeking H:
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG
methylation in colorectal, pancreatic, mammary, ovarian,
urothelial, and renal cell carcinomas and soft tissue sarcomas.
Virchows Arch. 458:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun H, Li K and Shen S: A study of the
role of Notch1 and JAG1 gene methylation in development of breast
cancer. Med Oncol. 33:352016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao YW, Wan GX, Sun JP, Cui XB, Hu JM,
Liang WH, Zheng YQ, Li WQ and Li F: Implications of the
Notch1-Snail/Slug-epithelial to mesenchymal transition axis for
lymph node metastasis in infiltrating ductal carcinoma. Kaohsiung J
Med Sci. 31:70–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li XJ, Ji MH, Zhong SL, Zh QB, Xu JJ, Zhao
JH and Tang JH: MicroRNA-34a modulates chemosensitivity of breast
cancer cells to adriamycin by targeting Notch1. Arch Med Res.
43:514–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bae Y, Yang T, Zeng HC, Campeau PM, Chen
Y, Bertin T, Dawson BC, Munivez E, Tao J and Lee BH: miRNA-34c
regulates Notch signaling during bone development. Hum Mol Genet.
21:2991–3000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bernardo BC, Gao XM, Winbanks CE, Boey EJ,
Tham YK, Kiriazis H, Gregorevic P, Obad S, Kauppinen S, Du XJ, et
al: Therapeutic inhibition of the miR-34 family attenuates
pathological cardiac remodeling and improves heart function. Proc
Natl Acad Sci USA. 109:17615–17620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jnawali HN, Lee E, Jeong KW, Shin A, Heo
YS and Kim Y: Anti-inflammatory activity of rhamnetin and a model
of its binding to c-Jun NH2-terminal kinase 1 and p38 MAPK. J Nat
Prod. 77:258–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji SY, Choi KM, Lee YS, Yu JY, Shin DM,
Lee S, Yoo KS, Lee YM, Yun YP and Yoo HS: Rhamnetin-induced
suppression of clonal expansion during early stage of adipogenesis.
Arch Pharm Res. 35:1083–1089. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee KP, Kim JE and Park WH: Cytoprotective
effect of rhamnetin on miconazole-induced H9c2 cell damage. Nutr
Res Pract. 9:586–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mattarei A, Biasutto L, Rastrelli F,
Garbisa S, Marotta E, Zoratti M and Paradisi C: Regioselective
O-derivatization of quercetin via ester intermediates. An improved
synthesis of rhamnetin and development of a new mitochondriotropic
derivative. Molecules. 15:4722–4736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma
HD, Sun HW, Hou MX, Yang YP and Feng F: Rhamnetin induces
sensitization of hepatocellular carcinoma cells to a small
molecular kinase inhibitor or chemotherapeutic agents. Biochim
Biophys Acta. 1860:1417–1430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajan SS, Sharma SC, Kumar N, Kumar R,
Singh G, Singh R and Tomar P: Clinical and cosmetic results of
breast boost radiotherapy in early breast cancer: A randomized
study between electron and photon. J Cancer Res Ther. 10:889–895.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Chlebowski RT, Anderson GL, Kuller
LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford
SA, et al: Sex hormone associations with breast cancer risk and the
mediation of randomized trial postmenopausal hormone therapy
effects. Breast Cancer Res. 16:R302014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mayer IA, Abramson VG, Isakoff SJ, Forero
A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y,
et al: Stand up to cancer phase Ib study of
pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole
in estrogen receptor-positive/human epidermal growth factor
receptor 2-negative metastatic breast cancer. J Clin Oncol.
32:1202–1209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pieme CA, Santosh GK, Tekwu EM, Askun T,
Aydeniz H, Ngogang JY, Bhushan S and Saxena AK: Fruits and barks
extracts of Zanthozyllum heitzii a spice from Cameroon induce
mitochondrial dependent apoptosis and G0/G1 phase arrest in human
leukemia HL-60 cells. Biol Res. 47:542014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang S, Li Y, Gao J, Zhan T, Li S, Luo A,
Chen H, Ding F, Wang X and Liu Z: MicroRNA-34 suppresses breast
cancer invasion and metastasis by directly targeting Fra-1.
Oncogene. 32:4294–4303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang J, Kim E, Kim W, Seong KM, Youn H,
Kim JW, Kim J and Youn B: Rhamnetin and cirsiliol induce
radiosensitization and inhibition of epithelial-mesenchymal
transition (EMT) by miR-34a-mediated suppression of Notch-1
expression in non-small cell lung cancer cell lines. J Biol Chem.
288:27343–27357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ng WL, Chen G, Wang M, Wang H, Story M,
Shay JW, Zhang X, Wang J, Amin AR, Hu B, et al: OCT4 as a target of
miR-34a stimulates p63 but inhibits p53 to promote human cell
transformation. Cell Death Dis. 5:e10242014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang SM, Tsai CF, Chen DR, Wang MY and
Yeh WL: p53 is a key regulator for osthole-triggered cancer
pathogenesis. Biomed Res Int. 2014:1752472014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hargraves KG, He L and Firestone GL:
Phytochemical regulation of the tumor suppressive microRNA,
miR-34a, by p53-dependent and independent responses in human breast
cancer cells. Mol Carcinog. 55:486–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng D, Tanikawa T, Li W, Zhao L, Vatan L,
Szeliga W, Wan S, Wei S, Wang Y, Liu Y, et al: Myeloid-derived
suppressor cells endow stem-like qualities to breast cancer cells
through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res.
76:3156–3165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui J, Li P, Liu X, Hu H and Wei W:
Abnormal expression of the Notch and Wnt/β-catenin signaling
pathways in stem-like ALDHCD44 cells correlates highly with Ki-67
expression in breast cancer. Oncol Lett. 9:1600–1606. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Portanova P, Notaro A, Pellerito O,
Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores
TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and
DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol.
43:121–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pamarthy S, Jaiswal MK, Kulshreshtha A,
Katara GK, Gilman-Sachs A and Beaman KD: The Vacuolar ATPase
a2-subunit regulates Notch signaling in triple-negative breast
cancer cells. Oncotarget. 6:34206–34220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shao S and Zhao X, Zhang X, Luo M, Zuo X,
Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the
epithelial-mesenchymal transition and invasion of breast cancer in
a Slug-dependent manner. Mol Cancer. 14:282015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang H, Li Y, Li T, Xu M, Chen Y, Wu C,
Dang X and Liu Y: Multifunctional core/shell nanoparticles
cross-linked polyetherimide-folic acid as efficient Notch-1 siRNA
carrier for targeted killing of breast cancer. Sci Rep. 4:70722014.
View Article : Google Scholar : PubMed/NCBI
|
